{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T13:28:47Z","timestamp":1794317327353,"version":"4.9.0"},"reference-count":112,"publisher":"American Academy of Pediatrics (AAP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,11,1]]},"abstract":"<jats:p>This technical report accompanies the American Academy of Pediatrics policy statement recommendations for COVID-19 vaccination during the 2026\u20132027 respiratory virus season. The rationale is presented for recommending vaccination in all infants and children 6 through 23 months of age, children 6 months through 18 years of age who are moderately or severely immunocompromised, and children 2 through 18 years of age in certain additional risk groups, including those at high risk of severe COVID-19, residents of long-term care facilities or other congregate settings, children who have never been vaccinated against COVID-19, and children whose household contacts are at high risk for severe COVID-19. The report synthesizes currently available evidence on SARS-CoV-2 epidemiology, disease burden, COVID-19 vaccine effectiveness, vaccine safety, and vaccine cost-effectiveness in pediatric populations. Additionally, the report provides an overview of available COVID-19 vaccine products, formulations, storage and handling considerations, and coadministration with other immunizations.<\/jats:p>","DOI":"10.1542\/peds.2026-079046","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T11:02:09Z","timestamp":1788346929000},"source":"Crossref","is-referenced-by-count":1,"title":["Recommendations for COVID-19 Vaccines in Infants, Children, and Adolescents, 2026\u20132027: Technical Report"],"prefix":"10.1542","volume":"158","author":[{"name":"Committee on Infectious Diseases","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2026,10,19]]},"reference":[{"issue":"5","key":"2026111008071760400_r1","article-title":"Recommendations for COVID-19 Vaccines in Infants, Children, and Adolescents: Policy Statement","volume":"158","author":"American Academy of Pediatrics, Committee on Infectious Diseases","year":"2026","journal-title":"Pediatrics."},{"issue":"49","key":"2026111008071760400_r2","doi-asserted-by":"crossref","first-page":"9171","DOI":"10.1016\/j.vaccine.2011.08.005","article-title":"Methods for developing evidence-based recommendations by the Advisory Committee on Immunization Practices (ACIP) of the U.S. Centers for Disease Control and Prevention (CDC)","volume":"29","author":"Ahmed","year":"2011","journal-title":"Vaccine."},{"key":"2026111008071760400_r3","author":"World Health Organization"},{"key":"2026111008071760400_r4","author":"Centers for Disease Control and Prevention"},{"key":"2026111008071760400_r5","author":"Centers for Disease Control and Prevention"},{"key":"2026111008071760400_r6","author":"Centers for Disease Control and Prevention","year":"2026"},{"key":"2026111008071760400_r7","author":"Centers for Disease Control and Prevention","year":"2026"},{"key":"2026111008071760400_r8","author":"World Health Organization","year":"2025"},{"key":"2026111008071760400_r9","author":"Centers for Disease Control and Prevention","year":"2026"},{"key":"2026111008071760400_r10","doi-asserted-by":"crossref","DOI":"10.1038\/s41390-026-05002-7","article-title":"Pediatric SARS-CoV-2 outcomes study (PECOS): 12-month longitudinal analysis of post-COVID symptoms in infected versus uninfected participants","author":"Montealegre Sanchez","year":"2026","journal-title":"Pediatr Res."},{"key":"2026111008071760400_r11","author":"Centers for Disease Control and Prevention"},{"key":"2026111008071760400_r12","author":"Centers for Disease Control and Prevention"},{"issue":"3","key":"2026111008071760400_r13","doi-asserted-by":"crossref","first-page":"e2025072788","DOI":"10.1542\/peds.2025-072788","article-title":"Hospitalization for COVID-19 and risk factors for severe disease among children: 2022\u20132024","volume":"156","author":"Free","year":"2025","journal-title":"Pediatrics."},{"key":"2026111008071760400_r14","author":"Ahmad","year":"2026"},{"key":"2026111008071760400_r15","author":"US Census Bureau","year":"2024"},{"issue":"42","key":"2026111008071760400_r16","doi-asserted-by":"crossref","first-page":"938","DOI":"10.15585\/mmwr.mm7342a1","article-title":"Genomic surveillance for SARS-CoV-2 variants: circulation of Omicron XBB and JN.1 lineages\u2014United States, May 2023\u2013September 2024","volume":"73","author":"Ma","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"2026111008071760400_r17","author":"Infectious Diseases Society of America","year":"2025"},{"key":"2026111008071760400_r18","author":"Centers for Disease Control and Prevention","year":"2025"},{"issue":"1","key":"2026111008071760400_r19","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/EDE.0000000000001908","article-title":"OpenSAFELY: effectiveness of COVID-19 vaccination in children and adolescents","volume":"37","author":"Andrews","year":"2026","journal-title":"Epidemiology."},{"issue":"1","key":"2026111008071760400_r20","doi-asserted-by":"crossref","first-page":"19","DOI":"10.15585\/mmwr.mm7101a4","article-title":"Risk factors for severe COVID-19 outcomes among persons aged \u226518 years who completed a primary COVID-19 vaccination series\u2014465 health care facilities, United States, December 2020\u2013October 2021","volume":"71","author":"Yek","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep."},{"issue":"12","key":"2026111008071760400_r21","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1093\/jpids\/piac086","article-title":"Primary and secondary attack rates by vaccination status after a SARS-CoV-2 B.1.617.2 (Delta) variant outbreak at a youth summer camp\u2014Texas, June 2021","volume":"11","author":"Baker","year":"2022","journal-title":"J Pediatric Infect Dis Soc."},{"issue":"5","key":"2026111008071760400_r22","doi-asserted-by":"crossref","first-page":"e2612609","DOI":"10.1001\/jamanetworkopen.2026.12609","article-title":"Recent COVID-19 vaccination and risk of SARS-CoV-2 transmission","volume":"9","author":"Benist","year":"2026","journal-title":"JAMA Netw Open."},{"issue":"49","key":"2026111008071760400_r23","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.15585\/mmwr.mm7349a2","article-title":"Use of additional doses of 2024\u20132025 COVID-19 vaccine for adults aged \u226565 years and persons aged \u22656 months with moderate or severe immunocompromise: recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2024","volume":"73","author":"Roper","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep."},{"issue":"2","key":"2026111008071760400_r24","doi-asserted-by":"crossref","first-page":"e2026075971","DOI":"10.1542\/peds.2026-075971","article-title":"Influenza, COVID-19, and RSV vaccinations for immunocompromised children and household contacts","volume":"158","author":"Kao","year":"2026","journal-title":"Pediatrics."},{"key":"2026111008071760400_r25","author":"Centers for Disease Control and Prevention","year":"2025"},{"key":"2026111008071760400_r26","doi-asserted-by":"crossref","first-page":"114873","DOI":"10.1016\/j.jpeds.2025.114873","article-title":"SARS-CoV-2-specific immune responses to vaccination in children and adolescents with suppressed immune systems: a prospective, observational study","volume":"289","author":"Brugha","year":"2026","journal-title":"J Pediatr."},{"issue":"17","key":"2026111008071760400_r27","doi-asserted-by":"crossref","first-page":"4549","DOI":"10.1182\/bloodadvances.2024013878","article-title":"COVID-19 mRNA vaccination responses in individuals with sickle cell disease: an ASH RC Sickle Cell Research Network Study","volume":"8","author":"Anderson","year":"2024","journal-title":"Blood Adv."},{"issue":"9","key":"2026111008071760400_r28","doi-asserted-by":"crossref","first-page":"e41606","DOI":"10.1097\/MD.0000000000041606","article-title":"Effect of immunomodulatory agents on the response to COVID-19 vaccination among patients with neuromuscular diseases: A single center experience","volume":"104","author":"Hsu","year":"2025","journal-title":"Medicine (Baltimore)."},{"issue":"7","key":"2026111008071760400_r29","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1093\/jpids\/piae052","article-title":"Risk factors for pediatric critical COVID-19: a systematic review and meta-analysis","volume":"13","author":"Aparicio","year":"2024","journal-title":"J Pediatric Infect Dis Soc."},{"issue":"5","key":"2026111008071760400_r30","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.3346\/jkms.2022.37.e35","article-title":"Risk factors for severe COVID-19 in children: a systematic review and meta-analysis","volume":"37","author":"Choi","year":"2022","journal-title":"J Korean Med Sci."},{"key":"2026111008071760400_r31","doi-asserted-by":"crossref","first-page":"1159269","DOI":"10.3389\/fimmu.2023.1159269","article-title":"The impact of immunocompromise on outcomes of COVID-19 in children and young people-a systematic review and meta-analysis","volume":"14","author":"Greenan-Barrett","year":"2023","journal-title":"Front Immunol."},{"issue":"2","key":"2026111008071760400_r32","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1093\/cid\/ciae133","article-title":"Pre-existing immunocompromising conditions and outcomes of acute COVID-19 patients admitted for pediatric intensive care","volume":"79","author":"Rowan","year":"2024","journal-title":"Clin Infect Dis."},{"issue":"3","key":"2026111008071760400_r33","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1093\/cid\/ciae602","article-title":"Community-acquired respiratory virus infections: a threat to long-term survivors after allogeneic stem cell transplant?","volume":"81","author":"Pi\u00f1ana","year":"2025","journal-title":"Clin Infect Dis."},{"issue":"2","key":"2026111008071760400_r34","doi-asserted-by":"crossref","first-page":"e2355727","DOI":"10.1001\/jamanetworkopen.2023.55727","article-title":"COVID-19 in pediatric patients with acute lymphoblastic leukemia or lymphoma","volume":"7","author":"Hashmi","year":"2024","journal-title":"JAMA Netw Open."},{"issue":"5","key":"2026111008071760400_r35","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1007\/s00467-023-06241-0","article-title":"COVID-19 disease among children and young adults enrolled in the North American Pediatric Renal Trials and Collaborative Studies registry","volume":"39","author":"Twichell","year":"2024","journal-title":"Pediatr Nephrol."},{"issue":"1","key":"2026111008071760400_r36","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1542\/hpeds.2021-006210","article-title":"COVID-19 and vaccination for residents and staff in pediatric long-term care facilities","volume":"12","author":"Nee","year":"2022","journal-title":"Hosp Pediatr."},{"issue":"2","key":"2026111008071760400_r37","doi-asserted-by":"crossref","first-page":"e2459672","DOI":"10.1001\/jamanetworkopen.2024.59672","article-title":"COVID-19 Vaccination and odds of post-COVID-19 condition symptoms in children aged 5 to 17 years","volume":"8","author":"Yousaf","year":"2025","journal-title":"JAMA Netw Open."},{"issue":"20","key":"2026111008071760400_r38","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1056\/NEJMoa2202826","article-title":"BNT162b2 protection against the Omicron variant in children and adolescents","volume":"386","author":"Price","year":"2022","journal-title":"N Engl J Med."},{"issue":"42","key":"2026111008071760400_r39","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.15585\/mmwr.mm7042e1","article-title":"Effectiveness of Pfizer-BioNTech mRNA vaccination against COVID-19 hospitalization among persons aged 12-18 years\u2014United States, June\u2013September 2021","volume":"70","author":"Olson","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep."},{"issue":"4","key":"2026111008071760400_r40","doi-asserted-by":"crossref","first-page":"883","DOI":"10.3390\/microorganisms14040883","article-title":"Effectiveness of COVID-19 vaccine boosters in children across pandemic and endemic periods","volume":"14","author":"Oliveira","year":"2026","journal-title":"Microorganisms."},{"issue":"7","key":"2026111008071760400_r41","doi-asserted-by":"crossref","first-page":"e2521009","DOI":"10.1001\/jamanetworkopen.2025.21009","article-title":"Pediatric COVID-19 Hospitalization Trends by Race and Ethnicity","volume":"8","author":"Anglin","year":"2025","journal-title":"JAMA Netw Open."},{"issue":"4","key":"2026111008071760400_r42","doi-asserted-by":"crossref","first-page":"e2020009951","DOI":"10.1542\/peds.2020-009951","article-title":"Racial and\/or Ethnic and Socioeconomic Disparities of SARS-CoV-2 Infection Among Children","volume":"146","author":"Goyal","year":"2020","journal-title":"Pediatrics."},{"issue":"3","key":"2026111008071760400_r43","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/ppe.12865","article-title":"Racial, ethnic and socioeconomic disparities in SARS-CoV-2 infection amongst children","volume":"36","author":"Mannheim","year":"2022","journal-title":"Paediatr Perinat Epidemiol."},{"issue":"46","key":"2026111008071760400_r44","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.15585\/mmwr.mm7146a3","article-title":"Sociodemographic Variation in Early Uptake of COVID-19 Vaccine and Parental Intent and Attitudes Toward Vaccination of Children Aged 6 Months-4 Years - United States, July 1-29, 2022","volume":"71","author":"Santibanez","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep."},{"issue":"1","key":"2026111008071760400_r45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.mm7201a1","article-title":"Racial and Ethnic Differences in COVID-19 Vaccination Coverage Among Children and Adolescents Aged 5-17 Years and Parental Intent to Vaccinate Their Children - National Immunization Survey-Child COVID Module, United States. -September 2022","volume":"72","author":"Valier","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"2","key":"2026111008071760400_r46","doi-asserted-by":"crossref","first-page":"e2024065938","DOI":"10.1542\/peds.2024-065938","article-title":"Spatial Accessibility and Uptake of Pediatric COVID-19 Vaccinations by Social Vulnerability","volume":"154","author":"Khazanchi","year":"2024","journal-title":"Pediatrics."},{"issue":"7","key":"2026111008071760400_r47","doi-asserted-by":"crossref","first-page":"e211724","DOI":"10.1001\/jamahealthforum.2021.1724","article-title":"Achieving Racial and Ethnic Equity in COVID-19 Vaccination: From Individual Readiness to Health System Readiness","volume":"2","author":"Grumbach","year":"2021","journal-title":"JAMA Health Forum."},{"key":"2026111008071760400_r48","author":"Centers for Disease Control and Prevention"},{"key":"2026111008071760400_r49","author":"Moderna","year":"2025"},{"key":"2026111008071760400_r50","author":"Moderna","year":"2025"},{"key":"2026111008071760400_r51","author":"Pfizer Inc","year":"2026"},{"key":"2026111008071760400_r52","author":"Novavax, Inc.","year":"2025"},{"key":"2026111008071760400_r53","author":"US Food and Drug Administration","year":"2026"},{"key":"2026111008071760400_r54","author":"World Health Organization","year":"2026"},{"key":"2026111008071760400_r55","author":"U.S. Food and Drug Administration"},{"key":"2026111008071760400_r56","author":"U.S. Food and Drug Administration"},{"key":"2026111008071760400_r57","author":"U.S. Food and Drug Administration"},{"key":"2026111008071760400_r58","author":"U.S. Food and Drug Administration"},{"key":"2026111008071760400_r59","author":"Centers for Disease Control and Prevention","year":"2024"},{"issue":"5","key":"2026111008071760400_r60","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.2023.27022","article-title":"Effectiveness of bivalent mRNA COVID-19 vaccines in preventing SARS-CoV-2 infection in children and adolescents aged 5 to 17 years","volume":"331","author":"Feldstein","year":"2024","journal-title":"JAMA."},{"key":"2026111008071760400_r61","doi-asserted-by":"crossref","first-page":"128474","DOI":"10.1016\/j.vaccine.2026.128474","article-title":"Effectiveness of the COVID-19 messenger RNA vaccine against symptomatic omicron infection in children aged 6\u00a0months to 11\u00a0years in Japan","volume":"79","author":"Aizawa","year":"2026","journal-title":"Vaccine."},{"key":"2026111008071760400_r62","doi-asserted-by":"crossref","first-page":"04250","DOI":"10.7189\/jogh.15.04250","article-title":"BNT162b2 COVID-19 vaccination uptake, safety, effectiveness, and waning in children and young people aged 5-11 years in Scotland","volume":"15","author":"Rudan","year":"2025","journal-title":"J Glob Health."},{"key":"2026111008071760400_r63","doi-asserted-by":"crossref","first-page":"105935","DOI":"10.1016\/j.puhe.2025.105935","article-title":"Long-term comparative effectiveness of BNT162b2 vaccine on SARS-CoV-2 infection in adolescents: A register-based real-world study from Denmark","volume":"248","author":"Bager","year":"2025","journal-title":"Public Health."},{"issue":"4","key":"2026111008071760400_r64","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1177\/15269248251383951","article-title":"Coronavirus disease 2019 (COVID-19) vaccination coverage and effectiveness among pediatric transplant recipients","volume":"35","author":"Cohen","year":"2025","journal-title":"Prog Transplant."},{"issue":"4","key":"2026111008071760400_r65","doi-asserted-by":"crossref","first-page":"e2023064446","DOI":"10.1542\/peds.2023-064446","article-title":"Vaccine effectiveness against long COVID in children","volume":"153","author":"Razzaghi","year":"2024","journal-title":"Pediatrics."},{"key":"2026111008071760400_r66","doi-asserted-by":"crossref","first-page":"102962","DOI":"10.1016\/j.eclinm.2024.102962","article-title":"Real-world effectiveness and causal mediation study of BNT162b2 on long COVID risks in children and adolescents","volume":"79","author":"Wu","year":"2024","journal-title":"EClinicalMedicine."},{"issue":"40","key":"2026111008071760400_r67","doi-asserted-by":"crossref","first-page":"607","DOI":"10.15585\/mmwr.mm7440a1","article-title":"Effectiveness of 2024-2025 COVID-19 vaccines in children in the United States\u2014VISION, August 29, 2024\u2013September 2, 2025","volume":"74","author":"Irving","year":"2025","journal-title":"MMWR Morb Mortal Wkly Rep."},{"issue":"33","key":"2026111008071760400_r68","doi-asserted-by":"crossref","first-page":"886","DOI":"10.15585\/mmwr.mm7233a2","article-title":"Effectiveness of monovalent and bivalent mrna vaccines in preventing COVID-19-associated emergency department and urgent care encounters among children aged 6 months-5 years\u2014VISION Network, United States, July 2022\u2013June 2023","volume":"72","author":"Link-Gelles","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep."},{"issue":"6","key":"2026111008071760400_r69","doi-asserted-by":"crossref","first-page":"e2025073212","DOI":"10.1542\/peds.2025-073212","article-title":"Effectiveness of 2023-2024 COVID-19 vaccines in children in the United States","volume":"156","author":"Irving","year":"2025","journal-title":"Pediatrics."},{"key":"2026111008071760400_r70","doi-asserted-by":"crossref","first-page":"114778","DOI":"10.1016\/j.jpeds.2025.114778","article-title":"BNT162b2 XBB.1.5-Adapted single dose vaccine uptake and effectiveness in children aged 5-17 years using linked claims and vaccine registries in California and Louisiana","volume":"286","author":"Andersen","year":"2025","journal-title":"J Pediatr."},{"issue":"12","key":"2026111008071760400_r71","doi-asserted-by":"crossref","first-page":"e2449944","DOI":"10.1001\/jamanetworkopen.2024.49944","article-title":"BNT162b2 XBB Vaccine for COVID-19 among children 5-17 years of age","volume":"7","author":"Tartof","year":"2024","journal-title":"JAMA Netw Open."},{"issue":"8","key":"2026111008071760400_r72","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1056\/NEJMoa2117995","article-title":"Effectiveness of BNT162b2 vaccine against critical Covid-19 in adolescents","volume":"386","author":"Olson","year":"2022","journal-title":"N Engl J Med."},{"key":"2026111008071760400_r73","doi-asserted-by":"crossref","first-page":"128262","DOI":"10.1016\/j.vaccine.2026.128262","article-title":"Estimates of SARS-CoV-2 vaccine effectiveness against COVID-19-associated hospitalisation in paediatric patients in Hong Kong during two successive SARS-CoV-2 epidemic waves dominated by the Omicron variant: A test-negative design study","volume":"75","author":"Okoli","year":"2026","journal-title":"Vaccine."},{"issue":"11","key":"2026111008071760400_r74","doi-asserted-by":"crossref","first-page":"e70239","DOI":"10.1002\/pds.70239","article-title":"Impact and effectiveness of COVID-19 mRNA vaccination against COVID-19 hospitalisation in paediatrics: a cohort study using two linked data sources in Spain","volume":"34","author":"Castillo-Cano","year":"2025","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"4","key":"2026111008071760400_r75","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1097\/INF.0000000000005109","article-title":"Effectiveness and safety of COVID-19 mRNA vaccines in children 6-17 years old: a population-based study in Madrid","volume":"45","author":"Hern\u00e1n","year":"2026","journal-title":"Pediatr Infect Dis J."},{"issue":"1","key":"2026111008071760400_r76","doi-asserted-by":"crossref","first-page":"10878","DOI":"10.1038\/s41598-026-45261-2","article-title":"Adverse events following SARS-CoV-2 mRNA vaccination in norwegian adolescents","volume":"16","author":"Bergstad Larsen","year":"2026","journal-title":"Sci Rep."},{"issue":"12","key":"2026111008071760400_r77","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S2352-4642(25)00247-0","article-title":"Vascular and inflammatory diseases after COVID-19 infection and vaccination in children and young people in England: a retrospective, population-based cohort study using linked electronic health records","volume":"9","author":"Sampri","year":"2025","journal-title":"Lancet Child Adolesc Health."},{"key":"2026111008071760400_r78","doi-asserted-by":"crossref","first-page":"114642","DOI":"10.1016\/j.jpeds.2025.114642","article-title":"Active surveillance for myocarditis and pericarditis in Canadian children from 2021 to 2022: a Canadian Immunization Monitoring Program ACTive Study","volume":"284","author":"Top","year":"2025","journal-title":"J Pediatr."},{"key":"2026111008071760400_r79","author":"National Academies of Sciences, Engineering, and Medicine","year":"2024"},{"issue":"4","key":"2026111008071760400_r80","doi-asserted-by":"crossref","first-page":"e248192","DOI":"10.1001\/jamanetworkopen.2024.8192","article-title":"Safety of ancestral monovalent BNT162b2, mRNA-1273, and NVX-CoV2373 COVID-19 vaccines in US children aged 6 months to 17 years","volume":"7","author":"Hu","year":"2024","journal-title":"JAMA Netw Open."},{"issue":"1","key":"2026111008071760400_r81","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1038\/s41467-024-47745-z","article-title":"Safety outcomes following COVID-19 vaccination and infection in 5.1 million children in England","volume":"15","author":"Copland","year":"2024","journal-title":"Nat Commun."},{"issue":"1","key":"2026111008071760400_r82","doi-asserted-by":"crossref","first-page":"e2023061894","DOI":"10.1542\/peds.2023-061894","article-title":"Safety of COVID-19 mRNA vaccination among young children in the Vaccine Safety Datalink","volume":"152","author":"Goddard","year":"2023","journal-title":"Pediatrics."},{"key":"2026111008071760400_r83","doi-asserted-by":"crossref","first-page":"128225","DOI":"10.1016\/j.vaccine.2026.128225","article-title":"Febrile seizure risk following monovalent COVID-19 mRNA vaccination in US children aged 2-5\u00a0years","volume":"75","author":"Anderson","year":"2026","journal-title":"Vaccine."},{"issue":"7","key":"2026111008071760400_r84","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.vaccine.2024.02.032","article-title":"Mortality risk after COVID-19 vaccination: A self-controlled case series study","volume":"42","author":"Xu","year":"2024","journal-title":"Vaccine."},{"issue":"27","key":"2026111008071760400_r85","doi-asserted-by":"crossref","first-page":"977","DOI":"10.15585\/mmwr.mm7027e2","article-title":"Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: update from the Advisory Committee on Immunization Practices\u2014United States, June 2021","volume":"70","author":"Gargano","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep."},{"issue":"4","key":"2026111008071760400_r86","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1001\/jama.2021.24110","article-title":"Myocarditis Cases reported after mRNA-based COVID-19 vaccination in the US from December 2020 to August 2021","volume":"327","author":"Oster","year":"2022","journal-title":"JAMA."},{"issue":"5","key":"2026111008071760400_r87","doi-asserted-by":"crossref","first-page":"e2022060295","DOI":"10.1542\/peds.2022-060295","article-title":"COVID-19 vaccine safety first year findings in adolescents","volume":"151","author":"Hesse","year":"2023","journal-title":"Pediatrics."},{"issue":"9","key":"2026111008071760400_r88","doi-asserted-by":"crossref","first-page":"347","DOI":"10.15585\/mmwr.mm7109e2","article-title":"Safety monitoring of COVID-19 vaccine booster doses among persons aged 12-17 years\u2014United States, December 9, 2021\u2013February 20, 2022","volume":"71","author":"Hause","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"2026111008071760400_r89","doi-asserted-by":"crossref","first-page":"100809","DOI":"10.1016\/j.jvacx.2026.100809","article-title":"Active surveillance of adverse events following immunisation in children: pre, during and post COVID-19 pandemic","volume":"30","author":"Soh","year":"2026","journal-title":"Vaccine X."},{"key":"2026111008071760400_r90","doi-asserted-by":"crossref","DOI":"10.1038\/s41569-026-01276-w","article-title":"Global epidemiology of myocarditis: disparities in age, sex and geography","author":"Klingel","year":"2026","journal-title":"Nat Rev Cardiol."},{"issue":"2","key":"2026111008071760400_r91","doi-asserted-by":"crossref","first-page":"e2022057313","DOI":"10.1542\/peds.2022-057313","article-title":"Safety of COVID-19 vaccination in United States children ages 5 to 11 years","volume":"150","author":"Hause","year":"2022","journal-title":"Pediatrics."},{"key":"2026111008071760400_r92","author":"Centers for Disease Control and Prevention","year":"2025"},{"key":"2026111008071760400_r93","doi-asserted-by":"crossref","first-page":"112022","DOI":"10.1016\/j.intimp.2024.112022","article-title":"Comparative safety profile of bivalent and original COVID-19 mRNA vaccines regarding myocarditis\/pericarditis: A pharmacovigilance study","volume":"133","author":"Chen","year":"2024","journal-title":"Int Immunopharmacol."},{"issue":"11","key":"2026111008071760400_r94","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/S2352-4642(22)00244-9","article-title":"Outcomes at least 90 days since onset of myocarditis after mRNA COVID-19 vaccination in adolescents and young adults in the USA: a follow-up surveillance study","volume":"6","author":"Kracalik","year":"2022","journal-title":"Lancet Child Adolesc Health."},{"issue":"7","key":"2026111008071760400_r95","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1001\/jamapediatrics.2023.1440","article-title":"Safety of the BNT162b2 COVID-19 vaccine in children aged 5 to 17 years","volume":"177","author":"Hu","year":"2023","journal-title":"JAMA Pediatr."},{"issue":"35","key":"2026111008071760400_r96","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.15585\/mmwr.mm7135a3","article-title":"COVID-19 mRNA vaccine safety among children aged 6 months-5 years\u2014United States, June 18, 2022\u2013August 21, 2022","volume":"71","author":"Hause","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep."},{"issue":"5152","key":"2026111008071760400_r97","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.15585\/mmwr.mm705152a1","article-title":"COVID-19 vaccine safety in children aged 5-11 years\u2014United States, November 3\u2013December 19, 2021","volume":"70","author":"Hause","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep."},{"issue":"23","key":"2026111008071760400_r98","doi-asserted-by":"crossref","first-page":"621","DOI":"10.15585\/mmwr.mm7223a2","article-title":"Safety monitoring of mRNA COVID-19 vaccine third doses among children aged 6 months-5 years\u2014United States, June 17, 2022\u2013May 7, 2023","volume":"72","author":"Hause","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep."},{"issue":"33","key":"2026111008071760400_r99","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.15585\/mmwr.mm7133a3","article-title":"Safety monitoring of Pfizer-BioNTech COVID-19 vaccine booster doses among children aged 5-11 years\u2014United States, May 17\u2013July 31, 2022","volume":"71","author":"Hause","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep."},{"issue":"2","key":"2026111008071760400_r100","doi-asserted-by":"crossref","first-page":"39","DOI":"10.15585\/mmwr.mm7202a5","article-title":"Safety monitoring of bivalent COVID-19 mRNA vaccine booster doses among children aged 5-11 years\u2014United States, October 12\u2013January 1, 2023","volume":"72","author":"Hause","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"2026111008071760400_r101","doi-asserted-by":"crossref","first-page":"128167","DOI":"10.1016\/j.vaccine.2025.128167","article-title":"Adverse events post-BNT162b2 vaccination in Japanese children","volume":"73","author":"Okabe","year":"2026","journal-title":"Vaccine."},{"issue":"31","key":"2026111008071760400_r102","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.15585\/mmwr.mm7031e1","article-title":"COVID-19 vaccine safety in adolescents aged 12-17 years\u2014United States, December 14, 2020\u2013July 16, 2021","volume":"70","author":"Hause","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep."},{"issue":"14","key":"2026111008071760400_r103","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1016\/j.vaccine.2023.02.067","article-title":"Anaphylaxis rates following mRNA COVID-19 vaccination in children and adolescents: Analysis of data reported to EudraVigilance","volume":"41","author":"Maltezou","year":"2023","journal-title":"Vaccine."},{"issue":"3","key":"2026111008071760400_r104","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.vaccine.2022.12.036","article-title":"A safety study evaluating non-COVID-19 mortality risk following COVID-19 vaccination","volume":"41","author":"Xu","year":"2023","journal-title":"Vaccine."},{"key":"2026111008071760400_r105","article-title":"Surveillance of adverse events following immunisation in Australia annual report, COVID-19 vaccines, 2022","volume":"49","author":"Huang","year":"2025","journal-title":"Commun Dis Intell (2018)."},{"key":"2026111008071760400_r106","author":"Rind","year":"2026"},{"key":"2026111008071760400_r107","author":"Centers for Disease Control and Prevention","year":"2024"},{"key":"2026111008071760400_r108","author":"Centers for Disease Control and Prevention","year":"2025"},{"key":"2026111008071760400_r109","doi-asserted-by":"crossref","first-page":"126629","DOI":"10.1016\/j.vaccine.2024.126629","article-title":"Risk of adverse events after Omicron XBB-adapted BNT162b2 COVID-19 vaccination in the United States","volume":"45","author":"Sun","year":"2025","journal-title":"Vaccine."},{"key":"2026111008071760400_r110","author":"Centers for Disease Control and Prevention","year":"2026"},{"key":"2026111008071760400_r111","author":"US Food and Drug Administration"},{"key":"2026111008071760400_r112","doi-asserted-by":"crossref","first-page":"105103","DOI":"10.1016\/j.ebiom.2024.105103","article-title":"Ipsilateral and contralateral coadministration of influenza and COVID-19 vaccines produce similar antibody responses","volume":"103","author":"Pattinson","year":"2024","journal-title":"EBioMedicine."}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2026-079046\/1978886\/pediatrics.2026079046.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2026-079046\/1978886\/pediatrics.2026079046.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T13:07:33Z","timestamp":1794316053000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/158\/5\/e2026079046\/208786\/Recommendations-for-COVID-19-Vaccines-in-Infants"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,19]]},"references-count":112,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,10,19]]},"published-print":{"date-parts":[[2026,11,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2026-079046","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,19]]},"article-number":"e2026079046"}}